Sanofi (XSWX:SAN) Cyclically Adjusted PS Ratio: (As of Jun. 27, 2026)


XSWX:SAN Sanofi SA XSWX:SAN
87 GF Score
Price CHF73.20
GF Value CHF104.30
! 2 Warning Signs
View Full Analysis

What is Sanofi Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sanofi  (XSWX:SAN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sanofi Cyclically Adjusted PS Ratio Related Terms


Sanofi Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Sanofi's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Cyclically Adjusted PS Ratio Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 2.92 2.76 2.79 2.40

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 0.00 2.79 0.00 2.40

XSWX:SAN vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi's Cyclically Adjusted PS Ratio falls into.


XSWX:SAN
87GF Score
Sanofi SA XSWX:SAN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sanofi's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Sanofi's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=35.568/120.9000*120.9000
=35.568

Current CPI (Dec25) = 120.9000.

Sanofi Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 28.788 100.650 34.580
201712 33.397 101.850 39.644
201812 32.074 103.470 37.477
201912 32.682 104.980 37.638
202012 32.051 104.960 36.919
202112 32.410 107.850 36.332
202212 31.847 114.160 33.727
202312 31.239 118.390 31.901
202412 32.916 119.950 33.177
202512 35.568 120.900 35.568

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.

Key valuation signals for XSWX:SAN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for XSWX:SAN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF104.30
GF Value